share_log

BRIEF-Shenzhen Chipscreen Biosciences Announces NMPA New Drug Approval Of Bilessglu In China

BRIEF-Shenzhen Chipscreen Biosciences Announces NMPA New Drug Approval Of Bilessglu In China

简介-深圳芯屏生物科学公司宣布NMPA新药在中国获得Bilessglu批准
reuters ·  2021/10/19 07:40

Oct 19 (Reuters) - Shenzhen Chipscreen Biosciences Co Ltd

路透10月19日电-深圳晶屏生物科学有限公司

688321.SS :

688321.SS:

* SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD - ANNOUNCES NMPA NEW DRUG APPROVAL OF BILESSGLU (CHIGLITAZAR SODIUM TABLETS) FOR ( TYPE 2 DIABETES) IN CHINA

*深圳CHIPSCREEN生物科学有限公司-宣布NMPA批准治疗2型糖尿病的BILESSGLU(CHIGLITAZAR钠片)在中国获得新药批准

Source text for Eikon: ID:nPn2nXW6va Further company coverage: 688321.SS

Eikon的源文本:ID:nPn2nXW6va进一步的公司报道:688321.SS

((Reuters.Briefs@thomsonreuters.com;))

(Reurs.Briefs@thomsonreurs.com;)

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发